New hope for tough lung cancers: experimental drug HRS-4508 enters Mid-Stage trial
NCT ID NCT07003321
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 38 times
Summary
This study tests a new drug called HRS-4508 in 120 people with advanced non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to see if the drug shrinks tumors and to check for side effects. Participants must be between 18 and 80 years old and in fairly good health otherwise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact
Conditions
Explore the condition pages connected to this study.